[Anaphylactic shock due to patent blue: four case report and review of literature].
OBJECTIVE
Description of four cases of anaphylactic shock with blue dye injection (bleu patenté V Guerbet 2.5%) during sentinel node biopsy for breast cancer.


METHODS
Women with breast carcinoma and combined approach with radioactive tracer and blue patent injection.


RESULTS
Four cases were observed, which means an incidence of 0.57%. We report one case of grade II anaphylactic reaction and three cases of grade III requiring active reanimation and adrenaline perfusion. One patient developed a pulmonary embolism during the postoperative period, but no death was observed.


CONCLUSIONS
We find an incidence of 1.06% of allergy but only 0.25% of anaphylactic shock (grade III). These rare but serious cases must weigh up the benefits and risks of using blue dye. We suggest using blue dye injection only in case of radioisotope detection failure. Of course, this approach must be evaluated.
Lucas
N
N
Service de chirurgie oncologique, centre Paul-Papin, Angers, France.
Interne
S Benay
SB
Laine
P
P
Nicolie
B
B
Fondrinier
E
E
D000328:Adult; D000707:Anaphylaxis / Q000139:chemically induced* / Q000453:epidemiology; D001943:Breast Neoplasms / Q000473:pathology; D004396:Coloring Agents; D005260:Female; D006801:Humans; D008875:Middle Aged; D012394:Rosaniline Dyes / Q000276:immunology*; D021701:Sentinel Lymph Node Biopsy
D004396:Coloring Agents; D012394:Rosaniline Dyes; C008769:sulfan blue